Moleculin Biotech, Inc. is a pre-clinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

Breaking through to brain tumors…

Brain tumors are among the most difficult cancers to treat, largely because of something called the “blood brain barrier”.  WP1122 was specifically designed to slip past the blood brain barrier, using the same chemical trickery that converts morphine into heroin. We compared WP1122 to the current standard of care, temozolomide, in live human brain tumors transplanted into mice and demonstrated that WP1122 is capable of outperforming temozolomide.

For further information on WP1122, click here.

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates regarding Moleculin and breakthrough Cancer related innovations!

You have Successfully Subscribed!